PFIZER INC Quarterly Deferred Income Tax Expense (Benefit) in USD from Q1 2010 to Q1 2024
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Pfizer Inc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2010 to Q1 2024.
- Pfizer Inc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$441M, a 26.3% increase year-over-year.
- Pfizer Inc annual Deferred Income Tax Expense (Benefit) for 2023 was -$3.44B, a 8.56% increase from 2022.
- Pfizer Inc annual Deferred Income Tax Expense (Benefit) for 2022 was -$3.76B, a 12.3% increase from 2021.
- Pfizer Inc annual Deferred Income Tax Expense (Benefit) for 2021 was -$4.29B, a 173% decline from 2020.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)